EGFR and non-small cell lung carcinoma: Patients with stage IV NSCLC and EGFR mutations treated with tyrosine kinase inhibitors experienced improved progression-free survival (PFS), increased response rate, better overall quality of life, and fewer side effects in comparison to those receiving standard platinum-based chemotherapy15.